Amy O’Donnell, J.D., M.D., is a neurologist who joined Biohaven as Vice President, Head of Pharmacovigilance after 18 years in the pharmaceutical industry. Amy spent the last 6 years at Janssen where she led the Safety Management Team for two Neuroscience drugs and served as medical lead for a medical affairs post-marketing study.